checkAd

     121  0 Kommentare SHL Announces Full-Year 2023 Results - Stable Revenue Growth Alongside Groundbreaking Clinical Milestones - Seite 2

    Erez Nachtomy, CEO of SHL, remarked: "The results from 2023 reflect our strategic approach towards stable growth and financial stability amidst the dynamic market landscape. Our achievements in Israel, the advancement of our Virtual Visit services in Germany, and our focused investments in the US market provide the fundament for further growth. Our commitment remains steadfast on driving growth, enhancing financial stability, and meeting our strategic milestones, all while delivering value to our customers and stakeholders and leading the charge in the telemedicine landscape."

    Conference Call 4 pm CET / 10 am ET / 5 pm Israel Time
    The conference call can be accessed live via the below dial-in numbers:

    From Europe

     

    +41 (0)58 310 50 00

    From the UK

     

    +44 (0) 207 107 06 13

    From the USA

     

    +1 (1) 631 570 56 13

    From Israel

     

    +972 3763 1173

    Toll free:

     

    1 80 921 44 27

    Local:

     

    +972 3763 1173

    Other international numbers are available here.

    After the presentation, there will be an open Q&A. The conference call is scheduled to last 40-60 minutes and will be held in English.

    The presentation is available on: www.shl-telemedicine.com/reports
    The Full-Year Report 2023 is available on: www.shl-telemedicine.com/reports
    SEC submission of the Full-Year Report and presentation is available on:
    https://www.shl-telemedicine.com/sec-filing/

    About SHL Telemedicine
    SHL Telemedicine is engaged in developing and marketing personal telemedicine systems and the provision of medical call center services, with a focus on cardiovascular and related diseases, to end users and to the healthcare community. SHL Telemedicine offers its services and personal telemedicine devices to subscribers utilizing telephonic and Internet communication technology. SHL is listed on the SIX Swiss Exchange (SHLTN, ISIN: IL0010855885, Security No.: 1128957) and on the Nasdaq Stock Exchange (SHLT, ISIN: US78423T2006, CUSIP: 78423T200). For more information, please visit our website at www.shl-telemedicine.com.

    Seite 2 von 4


    Aktuelle Themen


    Business Wire (engl.)
    0 Follower
    Autor folgen

    SHL Announces Full-Year 2023 Results - Stable Revenue Growth Alongside Groundbreaking Clinical Milestones - Seite 2 SHL Telemedicine Ltd. (NASDAQ: SHLT; SIX Swiss Exchange: SHLTN) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, announced today its results for the full-year 2023, highlighting fiscally …

    Auch bei Lesern beliebt

    Schreibe Deinen Kommentar

    Disclaimer